[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neoadjuvant-therapy-in-rectal-cancer-radiotherapy-folfox\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neoadjuvant-therapy-in-rectal-cancer-radiotherapy-folfox":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100468372",false,"NCT05378919","Neoadjuvant Therapy vs Standard Therapy in Locally Advanced Rectal Cancer","Evaluation and Comparison of the Efficacy of a New Standard Pre-operative Chemotherapy for Stage II and III Colorectal Cancer According to the FOLFOX4 Regimen With Routine Chemoradiation Therapy","RECTUM2015","Inclusion Criteria:\n\n* diagnosed with rectal adenocarcinoma;\n* radiologically measurable tumor size;\n* general condition (ECOG 0-2 points);\n* stage II or III rectal tumor clinically (pelvic MRI and endorectal ultrasound),\n* in the absence of long-term spread of the disease (confirmed by radiological examinations (computed tomography of the thorax and abdomen));\n* during preoperative proctoscopy, the tumor is detected 0 -15 cm from the anus;\n* Blood tests 28 days before the start of treatment:\n\nand general blood count: neutrophils greater than 1.5x10 9 \u002F l, platelets greater than 100 x 10 9 \u002F l, Hemoglobin greater than 80 g \u002F l, liver enzymes (Aspartate aminotransferase (AST\u002FGOT), alanine aminotransferase (ALT\u002FGPT) not more than 3 times upper limit), and renal function (creatinine up to 1.5 times the upper limit of normal) is normal; women of childbearing potential - negative pregnancy test;\n\n• A signed informed consent form.\n\nExclusion Criteria:\n\n* patients with signs of intestinal obstruction at the start of treatment;\n* previous lower abdominal radiation therapy;\n* other tumors over a five-year period;\n* pregnant or breastfeeding women;\n* men and women of childbearing potential who do not agree to use adequate contraception;\n* Patient co-morbidities that would make the patient unsuitable for this study or significantly interfere with the assessment of safety and toxicity.","ALL","18 Years",{"count":19,"type":20},250,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","Phase II, Multicenter, Open-label, Randomized Study evaluating neoadjuvant chemotherapy (FOLFOX4) in patients with stage II and III colorectal cancer with standard chemoradiation Defined by Magnetic Resonance Imaging",[26],"Neoadjuvant Therapy in Rectal Cancer, Radiotherapy, FOLFOX","RECRUITING","2022-05-12",{"date":30,"type":31},"2022-05-18","ACTUAL",{"date":33,"type":31},"2015-06-01",{"date":35,"type":20},"2027-06-01",{"name":37,"class":38},"Lithuanian University of Health Sciences","OTHER",""]